You just read:

Health Canada approves Rydapt™ (midostaurin), first targeted therapy for common form of acute myeloid leukemia (AML)(1)(2)

News provided by

Novartis Pharmaceuticals Canada Inc.

Dec 05, 2017, 05:59 ET